Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.

Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.

Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.

Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.

Abstract: In a method of monitoring an engine starting system in an engine, the engine starting system includes a charging system, a battery, a starter, a flywheel, and a controller. The controller and monitors can monitor components and systems associated with starting of an engine, such as engine or cranking speed, power cylinder unit compression, injection timing, and proper fuel delivery to predict and/or diagnose problems. For example, a charging system voltage is monitored and the charging system voltage is compared with predetermined charging system voltage values. Voltage of the battery is monitored and battery voltage is compared with predetermined battery voltage values. A signal to an operator is provided if one or more of the charging system voltage and the battery voltage are outside of predetermined ranges for the one or more of the charging system voltage and the battery voltage.

Abstract: An immunogenic agent which comprises a killed strain of Burkholderia pseudomallei, or a combination of components thereof which combination produces a protective immune response in an animal to whom it is administered, and which comprises at least two members selected from the group consisting of (i) a lipopolysaccharide of Burkholderia pseudomallei, (ii) a capsular polysaccharide of Burkholderia pseudomallei and (iii) a protein of Burkholderia pseudomallei or an immunogenic variant thereof or an immunogenic fragment of either of these, or a nucleic acid which expresses said protein, immunogenic variant or immunogenic fragment thereof in a host animal; for use in the prevention or treatment of infection by Burkholderia pseudomallei and/or Burkholderia mallei.

Abstract: Provided are anti-PAI-1 antibodies or antibody fragments and methods of using them.

Abstract: An immunogenic agent which comprises a killed strain of Burkholderia pseudomallei, or a combination of components thereof which combination produces a protective immune response in an animal to whom it is administered, and which comprises at least two members selected from the group consisting of (i) a lipopolysaccharide of Burkholderia pseudomallei, (ii) a capsular polysaccharide of Burkholderia pseudomallei and (iii) a protein of Burkholderia pseudomallei or an immunogenic variant thereof or an immunogenic fragment of either of these, or a nucleic acid which expresses said protein, immunogenic variant or immunogenic fragment thereof in a host animal; for use in the prevention or treatment of infection by Burkholderia pseudomallei and/or Burkholderia mallei.

Abstract: An immunogenic agent which comprises a killed strain of Burkholderia pseudomallei, or a combination of components thereof which combination produces a protective immune response in an animal to whom it is administered, and which comprises at least two members selected from the group consisting of (i) a lipopolysaccharide of Burkholderia pseudomallei, (ii) a capsular polysaccharide of Burkholderia pseudomallei and (iii) a protein of Burkholderia pseudomallei or an immunogenic variant thereof or an immunogenic fragment of either of these, or a nucleic acid which expresses said protein, immunogenic variant or immunogenic fragment thereof in a host animal; for use in the prevention or treatment of infection by Burkholderia pseudomallei and/or Burkholderia mallei.

Abstract: In a method of monitoring an engine starting system in an engine, the engine starting system includes a charging system, a battery, a starter, a flywheel, and a controller. The controller and monitors can monitor components and systems associated with starting of an engine, such as engine or cranking speed, power cylinder unit compression, injection timing, and proper fuel delivery to predict and/or diagnose problems. For example, a charging system voltage is monitored and the charging system voltage is compared with predetermined charging system voltage values. Voltage of the battery is monitored and battery voltage is compared with predetermined battery voltage values. A signal to an operator is provided if one or more of the charging system voltage and the battery voltage are outside of predetermined ranges for the one or more of the charging system voltage and the battery voltage.

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Abstract: An immunogenic agent which comprises a killed strain of Burkholderia pseudomallei, or a combination of components thereof which combination produces a protective immune response in an animal to whom it is administered, and which comprises at least two members selected from the group consisting of (i) a lipopolysaccharide of Burkholderia pseudomallei, (ii) a capsular polysaccharide of Burkholderia pseudomallei and (iii) a protein of Burkholderia pseudomallei or an immunogenic variant thereof or an immunogenic fragment of either of these, or a nucleic acid which expresses said protein, immunogenic variant or immunogenic fragment thereof in a host animal; for use in the prevention or treatment of infection by Burkholderia pseudomallei and/or Burkholderia mallei.

Abstract: A polypeptide derived from the periplasmic space of Yersinia pestis or a fragment or a variant of said polypeptide for use as a medicament is described. Pharmaceutical compositions comprising such polypeptides, such as OppA from Yersinia pestis, are also described and claimed. In a preferred embodiments the pharmaceutical composition further comprises existing protective antigens from Y. pestis such as F1 and V antigens. Such compositions are protective in mice and may be used as a vaccine for the prophylactic or therapeutic treatment of plague.

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Abstract: A hypersonic waverider aircraft is disclosed that includes a first engine and an inlet including a throat. The inlet is configured to generate three-dimensional flow compression during hypersonic flight with a weak shock wave that begins at the leading edge surfaces of the inlet and coalesces ahead of the throat, and a weak shock wave that begins at the point of coalescence of the weak shock wave and extends to the throat. The inlet includes a v-shaped lip open to freestream airflow in one side of the inlet.

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Abstract: A method of identifying peptides of an antigen of interest which are capable of recognition by or induction of cytotoxic T lymphocytes, comprises the steps of: ascertaining a "motif" of peptides which bind to a chosen HLA class I allele; providing peptides having this motif which are present in the known sequence of the antigen of interest; screening the peptides using an HLA assembly assay; and screening the resulting peptides for recognition by or induction of cytotoxic T lymphocytes. The above peptides have been identified by this method, and the peptides and vaccines containing them are also claimed.